Bedaquiline
- TRADE NAME: Sirturo (Janssen)
- INDICATIONS: Pulmonary multi-drug resistant tuberculosis
- CLASS: Antimycobacterial (including antitubercular), Diarylquinoline
- HALF-LIFE: 5.5 months
FDA APPROVAL DATE: 12/28/2012
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Ketoconazole, Rifabutin, Rifampin, Rifapentine, Strong CYP3A4 inducers or inhibitors
PREGNANCY CATEGORY: B
INCREASED RISK OF DEATH / QT PROLONGATION
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of bedaquiline in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 09/29/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric